298 related articles for article (PubMed ID: 26589433)
1. Pericytes Promote Malignant Ovarian Cancer Progression in Mice and Predict Poor Prognosis in Serous Ovarian Cancer Patients.
Sinha D; Chong L; George J; Schlüter H; Mönchgesang S; Mills S; Li J; Parish C; Bowtell D; Kaur P;
Clin Cancer Res; 2016 Apr; 22(7):1813-24. PubMed ID: 26589433
[TBL] [Abstract][Full Text] [Related]
2. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
3. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
[TBL] [Abstract][Full Text] [Related]
4. Long Non-coding RNA
Yim GW; Kim HJ; Kim LK; Kim SW; Kim S; Nam EJ; Kim YT
Cancer Res Treat; 2017 Jul; 49(3):656-668. PubMed ID: 27737536
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
Tucker DW; Getchell CR; McCarthy ET; Ohman AW; Sasamoto N; Xu S; Ko JY; Gupta M; Shafrir A; Medina JE; Lee JJ; MacDonald LA; Malik A; Hasselblatt KT; Li W; Zhang H; Kaplan SJ; Murphy GF; Hirsch MS; Liu JF; Matulonis UA; Terry KL; Lian CG; Dinulescu DM
Clin Cancer Res; 2018 Mar; 24(6):1389-1401. PubMed ID: 29263182
[No Abstract] [Full Text] [Related]
6. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis.
Takahashi Y; Koyanagi T; Suzuki Y; Saga Y; Kanomata N; Moriya T; Suzuki M; Sato Y
Mol Cancer Res; 2012 Sep; 10(9):1135-46. PubMed ID: 22826464
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
Hu L; Cong L
Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
[TBL] [Abstract][Full Text] [Related]
8. Sterol regulatory element-binding protein 1 is required for ovarian tumor growth.
Nie LY; Lu QT; Li WH; Yang N; Dongol S; Zhang X; Jiang J
Oncol Rep; 2013 Sep; 30(3):1346-54. PubMed ID: 23818099
[TBL] [Abstract][Full Text] [Related]
9. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
10. Proteomics analysis to reveal biological pathways and predictive proteins in the survival of high-grade serous ovarian cancer.
Xie H; Wang W; Sun F; Deng K; Lu X; Liu H; Zhao W; Zhang Y; Zhou X; Li K; Hou Y
Sci Rep; 2017 Aug; 7(1):9896. PubMed ID: 28852147
[TBL] [Abstract][Full Text] [Related]
11. High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.
Sopo M; Sallinen H; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Anttila M
PLoS One; 2020; 15(11):e0241484. PubMed ID: 33151982
[TBL] [Abstract][Full Text] [Related]
12.
Xu Z; Zhuang L; Wang X; Li Q; Sang Y; Xu J
Future Oncol; 2020 Sep; 16(25):1921-1930. PubMed ID: 32915667
[No Abstract] [Full Text] [Related]
13. Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival.
Corvigno S; Wisman GB; Mezheyeuski A; van der Zee AG; Nijman HW; Åvall-Lundqvist E; Östman A; Dahlstrand H
Oncotarget; 2016 Apr; 7(14):18573-84. PubMed ID: 26918345
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma.
Jung SG; Kwon YD; Song JA; Back MJ; Lee SY; Lee C; Hwang YY; An HJ
Cancer Sci; 2010 Sep; 101(9):1977-83. PubMed ID: 20624166
[TBL] [Abstract][Full Text] [Related]
15. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.
Shin K; Kim KH; Yoon MS; Suh DS; Lee JY; Kim A; Eo W
Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740
[TBL] [Abstract][Full Text] [Related]
16. The potential prognostic value of cathepsin D protein in serous ovarian cancer.
Chai Y; Wu W; Zhou C; Zhou J
Arch Gynecol Obstet; 2012 Aug; 286(2):465-71. PubMed ID: 22476353
[TBL] [Abstract][Full Text] [Related]
17. Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival.
Gu Y; Li F; Qian N; Chen X; Wang H; Wang J
J Clin Pathol; 2016 May; 69(5):448-53. PubMed ID: 26468391
[TBL] [Abstract][Full Text] [Related]
18. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.
Yang G; Rosen DG; Liu G; Yang F; Guo X; Xiao X; Xue F; Mercado-Uribe I; Huang J; Lin SH; Mills GB; Liu J
Clin Cancer Res; 2010 Aug; 16(15):3875-86. PubMed ID: 20505188
[TBL] [Abstract][Full Text] [Related]
19. Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer.
Medrano M; Communal L; Brown KR; Iwanicki M; Normand J; Paterson J; Sircoulomb F; Krzyzanowski P; Novak M; Doodnauth SA; Saiz FS; Cullis J; Al-Awar R; Neel BG; McPherson J; Drapkin R; Ailles L; Mes-Massons AM; Rottapel R
Cell Rep; 2017 Mar; 18(10):2343-2358. PubMed ID: 28273451
[TBL] [Abstract][Full Text] [Related]
20. Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.
Ciucci A; Zannoni GF; Buttarelli M; Lisi L; Travaglia D; Martinelli E; Scambia G; Gallo D
Oncotarget; 2016 Feb; 7(7):8155-71. PubMed ID: 26797759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]